What Is AOD-9604? A Research Overview of the HGH Fragment 176-191 Analog

AOD-9604 HGH fragment 176-191 research peptide Durham Peptides Canada

AOD-9604 occupies a distinctive position in the peptide research field — it's a synthetic fragment of human growth hormone designed to isolate one specific aspect of GH biology (lipolytic activity) while avoiding the broader effects of full-length growth hormone. The compound has an unusually thorough research history, including formal pharmaceutical clinical trials through the company that developed it, and continues to appear in published research literature on fat metabolism and lipid biology.

This article provides a research-focused overview of AOD-9604 — its origin from human growth hormone research, the structural features that distinguish it, the mechanism studied in published research, the clinical research history, and the Canadian research peptide context.

AOD-9604 is now available in the Durham Peptides catalog as AOD-9604 5mg.

For the broader growth hormone-related peptide context, see Sermorelin, CJC-1295, and Ipamorelin: A Research Overview of Growth Hormone Peptides and What Is Tesamorelin?.

The Origin: Isolating GH's Lipolytic Activity

Human growth hormone (hGH) is a 191-amino-acid protein with multiple biological activities. Some of these activities — like growth promotion through IGF-1 signaling — depend on activation of the GH receptor and subsequent downstream signaling cascades. Others, particularly the lipolytic effects on adipose tissue, appear to operate through different mechanisms.

In the early 1990s, researchers identified that the C-terminal region of human growth hormone — specifically amino acids 176 through 191 — was responsible for much of the hormone's lipolytic activity. This 16-amino-acid sequence, known as HGH Fragment 176-191, could stimulate fat breakdown in laboratory models without engaging the full set of GH receptor signaling pathways.

Scientists at Metabolic Pharmaceuticals — an Australian biotechnology company — took this discovery further. They modified the native fragment by adding a tyrosine residue to the N-terminus, creating what would become known as AOD-9604 (originally short for "Anti-Obesity Drug 9604"). The N-terminal tyrosine modification was designed to enhance stability and improve the practical research half-life of the compound compared to the unmodified fragment.

AOD-9604 Structure

AOD-9604 consists of:

• The C-terminal 16 amino acids of human growth hormone (residues 176-191)

• An additional tyrosine residue at the N-terminus

The full sequence is therefore Tyr-hGH(177-191) — a 17-amino-acid peptide that retains the lipolytic-relevant region of hGH plus the tyrosine cap that distinguishes it from the unmodified HGH Fragment 176-191.

This is a critical structural distinction. AOD-9604 and HGH Fragment 176-191 are often discussed interchangeably in research literature, but they're not identical:

• HGH Fragment 176-191 is the natural sequence of amino acids 176 through 191 at the C-terminal end of human growth hormone

• AOD-9604 is the same core sequence with an additional N-terminal tyrosine residue

The N-terminal tyrosine addition produces measurable differences:

• Enhanced stability. The modification improves resistance to enzymatic degradation, extending functional half-life in research applications

• Improved potency. Comparative studies indicate AOD-9604 demonstrates stronger lipolytic activity per unit dose than the unmodified fragment

• Better-characterized research base. AOD-9604 was the specific compound used in the Metabolic Pharmaceuticals clinical development program, producing a more substantial published clinical literature

For Canadian researchers, the practical implication is that AOD-9604 is the more commonly studied of the two compounds in modern research peptide work. The Durham Peptides catalog includes AOD-9604 specifically — see AOD-9604 5mg.

For the manufacturing context, see Peptide Manufacturing 101: How Research Peptides Are Made From Amino Acids to Vial.

The Research Mechanism

The published research literature has investigated AOD-9604's effects on lipid metabolism through several distinct mechanisms:

Lipolysis stimulation. Multiple published studies have documented AOD-9604's effects on stimulating the breakdown of stored triglycerides into free fatty acids. The mechanism appears to operate through pathways related to β3-adrenergic signaling in some research contexts, though the complete mechanistic picture continues to develop in published research.

Lipogenesis inhibition. Beyond stimulating fat breakdown, research has documented AOD-9604's effects on inhibiting the formation of new fat cells (adipogenesis) and the storage of fats in adipose tissue.

Receptor-independent activity. Notably, AOD-9604's research mechanism appears to operate independently of growth hormone receptor activation. This distinguishes the compound from full-length growth hormone or GHRH analogs that work through GH-related signaling pathways.

No effect on IGF-1 or glucose. Research has documented that AOD-9604 does not increase IGF-1 levels or affect insulin sensitivity in the way that full-length growth hormone or GHRH analogs do. The compound isolates the lipolytic aspect of GH biology without

engaging the broader growth-promoting or metabolic effects.

For pharmacokinetic context, see Peptide Half-Life Explained: Why Some Peptides Last Hours and Others Days.

The Clinical Research History

AOD-9604 has an unusually thorough clinical research history for a research peptide. Metabolic Pharmaceuticals — the Australian biotechnology company that developed the compound — pursued formal pharmaceutical clinical development through Phase IIb trials.

The clinical development included:

• Phase 1 pharmacokinetic and safety studies

• Phase 2 dose-finding studies

• Phase IIb efficacy trials examining weight management research outcomes

Important context: The Phase IIb efficacy trials did not meet their efficacy endpoints, and clinical development for the original therapeutic indication was halted. AOD-9604 has not received regulatory approval as a pharmaceutical product for any indication. The compound is listed by the FDA as a bulk drug substance that is not FDA-approved.

This history matters for Canadian researchers entering the AOD-9604 research category: the compound has a more substantial clinical research base than many research peptides, but the clinical research did not produce the efficacy outcomes the original developers anticipated. Research peptide researchers can draw from the published clinical pharmacology data while understanding that pharmaceutical efficacy was not established.

For the broader regulatory context, see Are Peptides Legal in Canada? A Complete Guide to Research Peptide Laws.

How AOD-9604 Differs from Other Research Peptide Categories

AOD-9604 occupies a distinct position relative to other research peptide categories:

Different from GHRH analogs. Tesamorelin, sermorelin, and CJC-1295 are GHRH analogs that prompt the pituitary's release of endogenous growth hormone — they engage the upstream GH-releasing pathway. AOD-9604 doesn't engage GH receptors and doesn't influence GH release; it's a downstream fragment with isolated lipolytic activity.

Different from GH secretagogues. Ipamorelin and other ghrelin receptor agonists also work upstream of GH release, through the ghrelin receptor pathway. AOD-9604 is not a secretagogue.

Different from metabolic peptides. Semaglutide, tirzepatide, and retatrutide work through incretin receptors (GLP-1, GIP, glucagon). AOD-9604 doesn't engage these receptors.

Different from tissue-repair peptides. BPC-157 and TB-500 work through angiogenic and cell migration pathways. AOD-9604's mechanism is specifically about lipid metabolism rather than tissue repair.

For coverage of growth hormone peptide categories more broadly, see GHRH vs GHRP: Understanding the Two Categories of Growth Hormone Peptides.

Manufacturing and Quality Considerations

AOD-9604 is produced via Solid-Phase Peptide Synthesis (SPPS) using synthetic amino acids — the modern manufacturing standard for research peptides. The N-terminal tyrosine modification is incorporated as a specific synthetic step.

For quality verification, the standard research peptide framework applies:

Identity verification. Mass spectrometry should confirm the molecular weight matches AOD-9604's expected value, including the tyrosine modification mass. The molecular weight should distinguish AOD-9604 from the unmodified HGH Fragment 176-191. See How to Read a Janoshik COA: HPLC, Mass Spec, and the Unique Key Explained.

Purity verification. ≥99% HPLC purity is the research-grade standard. See Peptide Purity: Why 99% Matters.

Third-party verification. Independent COA via Janoshik Analytical is the research-grade industry standard. Durham Peptides publishes the COA for AOD-9604 5mg at durhampeptides.ca/lab-results.

Storage. AOD-9604, like other lyophilized research peptides, requires standard refrigerated or frozen storage. Reconstituted with bacteriostatic water, shelf life follows the typical research peptide framework. See Peptide Storage & Shelf Life: How to Store BPC-157, Tirzepatide, and Other Research Peptides.

Reconstitution. Standard research peptide reconstitution practices apply. See How to Reconstitute Peptides: A Step-by-Step Guide for Researchers and Peptide Reconstitution Calculator Guide.

Regulatory Status in Canada

AOD-9604 is not approved by Health Canada for human or veterinary therapeutic use. The compound has not received pharmaceutical approval in any jurisdiction. It exists in the standard research peptide framework — sold for laboratory and research applications under research-use-only framing.

For the broader Canadian regulatory framework, see Are Peptides Legal in Canada? A Complete Guide to Research Peptide Laws and Peptide Certifications Explained: GMP, ISO, USP, and What Actually Matters.

Frequently Asked Questions

What is AOD-9604? A synthetic peptide consisting of the C-terminal 16 amino acids of human growth hormone (residues 176-191) plus an added N-terminal tyrosine residue. Developed by Metabolic Pharmaceuticals (Australia) to isolate the lipolytic activity of growth hormone without the broader GH-related effects.

Is AOD-9604 the same as HGH Fragment 176-191? Not exactly. HGH Fragment 176-191 is the natural unmodified C-terminal sequence. AOD-9604 is the same core sequence with an added N-terminal tyrosine residue that enhances stability and lipolytic activity. AOD-9604 has the more substantial published clinical research base.

Does AOD-9604 work like growth hormone? No. AOD-9604 isolates the lipolytic activity of growth hormone without engaging GH receptors or affecting IGF-1 levels. It doesn't promote growth or affect glucose homeostasis the way full-length GH does.

Does Durham Peptides sell AOD-9604? Yes. AOD-9604 5mg is now available with full Janoshik third-party testing and Canadian-domestic shipping.

Is AOD-9604 FDA-approved? No. AOD-9604 has not received pharmaceutical approval in any jurisdiction. Phase IIb clinical trials failed to meet efficacy endpoints, and clinical development was discontinued. The compound is listed by the FDA as a bulk drug substance that is not approved.

Is AOD-9604 approved by Health Canada? No. AOD-9604 is not approved by Health Canada for human or veterinary therapeutic use. It is sold under research-use-only framing for laboratory and research applications.

What's AOD-9604's research mechanism? The published research literature has investigated AOD-9604's effects on stimulating lipolysis (fat breakdown), inhibiting lipogenesis (new fat formation), and operating independently of growth hormone receptors. Mechanism research continues to develop in published literature.

How is AOD-9604 different from GHRH analogs like tesamorelin? GHRH analogs (sermorelin, CJC-1295, tesamorelin) work upstream of GH release by prompting the pituitary's natural pulsatile release of endogenous growth hormone. AOD-9604 doesn't engage GH receptors or affect GH release — it's a downstream fragment with isolated lipolytic activity.

Is AOD-9604 vegan? Yes. Modern AOD-9604 is manufactured via Solid-Phase Peptide Synthesis with synthetic amino acids — the modern standard. See Vegan Peptides.

What's AOD-9604's clinical research history? Metabolic Pharmaceuticals (Australian company) pursued formal pharmaceutical development including Phase 1, Phase 2, and Phase IIb clinical trials. The Phase IIb efficacy trials did not meet their efficacy endpoints, and clinical development for the original therapeutic indication was halted.

How is AOD-9604 manufactured? Solid-Phase Peptide Synthesis (SPPS) using synthetic amino acids, with the N-terminal tyrosine modification incorporated as a specific synthetic step. See Peptide Manufacturing 101.

Where does AOD-9604 fit in the peptide research field? In a distinct corner — separate from metabolic peptides (incretin receptors), GHRH analogs (upstream GH release), tissue-repair peptides, and other categories. AOD-9604 has a specific isolated mechanism related to fat metabolism that doesn't directly overlap with other peptide categories.

Final Thoughts

AOD-9604 is one of the more thoroughly characterized research peptides in terms of clinical research base. The combination of the Australian pharmaceutical development program (which produced substantial published clinical data) plus the continued research peptide presence makes AOD-9604 a well-documented research compound. The

structural design — isolating the lipolytic-relevant region of human growth hormone with the stability-enhancing N-terminal modification — represents a thoughtful approach to studying GH lipolytic biology without the broader GH-related effects.

For Canadian researchers, AOD-9604 is now available through Durham Peptides as AOD-9604 5mg — manufactured via Solid-Phase Peptide Synthesis, third-party tested by Janoshik Analytical, and sold with the same research-use-only framework that applies to the entire catalog.

For continued reading, see What Is Tesamorelin?, Sermorelin, CJC-1295, and Ipamorelin Research Overview, GHRH vs GHRP, Peptide Half-Life Explained, and Peptide Research Trends 2026.

Browse the complete Durham Peptides catalog at durhampeptides.ca/category/all-products. View all Janoshik-verified COAs at durhampeptides.ca/lab-results.

Selected Research References

1. Heffernan M, Summers RJ, Thorburn A, et al. The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice. Endocrinology. 2001;142(12):5182-5189. https://pubmed.ncbi.nlm.nih.gov/11713213/

2. Heffernan MA, Thorburn AW, Fam B, et al. Increase of Fat Oxidation and Weight Loss in Obese Mice Caused by Chronic Treatment with Human Growth Hormone or a Modified C-Terminal Fragment. International Journal of Obesity and Related Metabolic Disorders. 2001;25(10):1442-1449. https://pubmed.ncbi.nlm.nih.gov/11673763/

3. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic Studies of a Synthetic Lipolytic Domain (AOD9401) of Human Growth Hormone. Hormone Research. 2000;53(6):274-278. https://pubmed.ncbi.nlm.nih.gov/11146367/

4. Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism. 2013;3(1-2):7-15. Published clinical safety data on AOD-9604.

5. Wu Z, Bidlingmaier M, Friess SC, et al. A New Nonradioactive Immunoassay for Detection of Recombinant Human Growth Hormone Capable of Distinguishing It from Pituitary Growth Hormone in Plasma. Journal of Clinical Endocrinology and Metabolism. 1999. Background reference on growth hormone characterization.

6. Lau JL, Dunn MK. Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions. Bioorganic & Medicinal Chemistry. 2018;26(10):2700-2707. https://pubmed.ncbi.nlm.nih.gov/28720325/

All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease. This article is informational and does not constitute medical advice.